logo
  

Karyopharm Therapeutics Inc. Q1 Loss increases, but beats estimates

Karyopharm Therapeutics Inc. (KPTI) revealed Loss for its first quarter that increased from the same period last year but beat the Street estimates.

The company's earnings came in at -$37.36 million, or -$0.32 per share. This compares with -$34.13 million, or -$0.30 per share, in last year's first quarter.

Analysts on average had expected the company to earn -$0.33 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 14.4% to $33.13 million from $38.70 million last year.

Karyopharm Therapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q1): -$37.36 Mln. vs. -$34.13 Mln. last year.
-EPS (Q1): -$0.32 vs. -$0.30 last year.
-Revenue (Q1): $33.13 Mln vs. $38.70 Mln last year.

-Guidance:
Full year revenue guidance: $140 Mln-$160 Mln

For comments and feedback contact: editorial@rttnews.com

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
RELATED NEWS
Follow RTT